CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
The Cancer Research Institute (CRI) and the Canadian Cancer Trials Group (CCTG) announced the enrollment of the first patient in the third substudy IND240C of their ongoing Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC). The IND240C (IPROC)trial is a phase 2, multi-center, platform study designed to test novel immunotherapy combinations for high-grade serous ovarian cancer, an aggressive subtype that has poor prognoses and limited therapeutic options. Platform trials employ a master protocol that enables the efficient evaluation of multiple treatment combinations within a single, adaptive framework. Each new cohort functions as a distinct, independent trial—allowing researchers to rapidly introduce and test promising therapies in targeted patient populations. Building on the first two substudies (A and B)—which evaluated a PD-L1 inhibitor in combination with two distinct antibody-drug conjugates (ADCs)—Cohort C marks a significant expansion of the IPROC study. This new sub-study introduces both a new therapeutic combination and a broader patient population. For the first time in this trial, patients with clear cell ovarian cancer, an aggressive subtype, will be enrolled alongside patients with high-grade serous ovarian cancer.
Pausing endocrine treatment to attempt pregnancy can be considered - no additional risk of recurrences after 5 years.
Results from the primary analysis of the ctDNA-negative cohort from the international DYNAMIC-III (CO.29) clinical trial were presented during the Presidential Symposium of the European Society for Medical Oncology Congress in Berlin
Pausing endocrine treatment to attempt pregnancy can be considered - no additional risk of recurrences after 5 years. The MAC18 (POSITIVE) study, evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy long-term analysis was presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.
The CCTG SR.8 (HARMONY) clinical trial has been awarded almost 1.5 million through the CIHR spring Project Grant Program. A phase III study that addresses a significant unmet need in the treatment of high-risk soft-tissue sarcoma (STS).
The recently opened BR38 clinical trial is exploring whether adding stereotactic body radiotherapy (SBRT) to the current treatment of immunotherapy (with or without chemotherapy) can improve outcomes for patients with metastatic non-small cell lung cancer (NSCLC) and limited disease progression (oligoprogression).
In an important clinical trial research finding for advanced breast cancer treatment, the Canadian Cancer Trials Group (CCTG) has announced the results from the MA.40 clinical trial. These study results highlight the importance of targeting the AKT pathway to slow tumour progression in patients with advanced estrogen receptor-positive (ER+)/HER2-negative breast cancer.
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)
Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials
NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma (NAPStAR)
LoTam: Low-Dose Tamoxifen for Patients with Molecular Low-risk Early-Stage Breast Cancer
No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
We are pleased to welcome Lesley Beaton as the new patient representative supporting the Gastrointestinal Disease Site Committee.
Lesley lives in Vancouver, BC, and brings both scientific and personal experience to her role. She spent more than three decades working in microbiology and regulatory compliance with Health Canada, gaining a scientific perspective on healthcare systems.
Please join us in welcoming Catherine Caule, who is the new patient representative supporting the Hematology Disease Site Committee.
Catherine is a long-time health advocate based in Ottawa, Ontario, and a 25-year member of the Lymphoma Support Group of Ottawa. After being diagnosed with advanced Hodgkin Lymphoma and participating in a clinical trial for relapsed disease, she became a passionate voice for patient-centered care and equitable access.
